Focus Partners Wealth’s Akebia Therapeutics AKBA Stock Holding History

Focus Partners Wealth’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$41.5K	Sell	29,833 -16,867	-36%	-$23.2K	﹤0.01%	2589
2025 Q4	$75.2K	Buy	46,700 +16,109	+53%	+$33.7K	﹤0.01%	2577
2025 Q3	$86.5K	Buy	30,591 +17,324	+131%	+$57.6K	﹤0.01%	2137
2025 Q2	$48.3K	Buy	13,267 +1,876	+16%	+$5.16K	﹤0.01%	1978
2025 Q1	$21.2K	Buy	11,391 +499	+5%	+$1.02K	﹤0.01%	1872
2024 Q4	$20.7K	Buy	+10,892	New	+$18.9K	﹤0.01%	1847
2024 Q3	–	Sell	-10,575	Closed	-$14K	–	1570
2024 Q2	$14K	Buy	10,575 +37	+0.4%	+$46	﹤0.01%	1222
2024 Q1	$13K	Buy	+10,538	New	+$16.8K	﹤0.01%	978

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Focus Partners Wealth's AKBA Position: Q1 2026 in Review

Focus Partners Wealth reduced its Akebia Therapeutics (AKBA) stake by 36% in Q1 2026, selling an estimated $23.2K and leaving 29,833 shares worth $41.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2589.

Focus Partners Wealth first reported a position in AKBA in Q1 2024 and has held it in 8 quarters since. The position peaked at $86.5K in Q3 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

Focus Partners Wealth held 29,833 shares of Akebia Therapeutics worth $41.5K as of Q1 2026.
Focus Partners Wealth sold 16,867 Akebia Therapeutics shares in Q1 2026, an estimated $23.2K.
Akebia Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q1 2026, its #2589 holding.
Focus Partners Wealth first reported a position in Akebia Therapeutics in Q1 2024 and has held it in 8 quarters since.
Focus Partners Wealth's Akebia Therapeutics position peaked at $86.5K in Q3 2025.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.